不同剂型硝苯吡啶治疗老年原发性高血压98例临床观察

目的　观察常规剂型与控释剂型硝苯吡啶治疗老年原发性高血压的疗效及心率、血脂、血糖、肾功能的影响。方法　选择本院住院患者 98例 ,均确诊为老年原发性高血压。病程 8个月至 2 0年 ,随机分成两组 :5 1例给予口服硝苯吡啶控释片 ,每日 1次 30mg。 4 7例给予口服硝苯吡啶片 ,每日 3次 ,每次 10mg ,观察疗程 6周。结果　与硝苯吡啶组比较 ,硝苯吡啶控释片降压效果更明显 ,不干扰HRV昼夜变化节律 ,两组患者治疗前后血糖、血脂无明显变化。结论　硝苯吡啶及其控制释片均可有效降低血压 ,对糖脂代谢无影响 ,硝苯吡啶控制片降低血压更平稳和持久。     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者疗效的影响

目的 研究低频电刺激周围神经对脑梗死偏瘫伴偏身感觉障碍患者感觉功能、运动功能及日常生活活动(ADL)能力的影响.方法 将61例急性脑梗死偏瘫伴偏身感觉障碍患者随机分为治疗组及对照组.2组患者均给予常规药物及康复治疗,治疗组患者在此基础上采用低频脉冲电刺激偏瘫侧肢体周围神经(对感觉障碍显著部位重点刺激).于治疗前及治疗14 d后分别采用简化Fugl-Meyer评分、Lindmark评分及改良Barthel指数评分(MBI)对2组患者肢体感觉、运动功能和ADL能力进行评定,结果 经14 d治疗后,发现2组患者肢体感觉、运动功能及ADL能力均较治疗前明显提高(均P＜0.01或0.05),且治疗组患者上述指标的改善幅度均显著优于对照组,组间差异具有统计学意义(均P＜0.01).结论 在常规治疗脑卒中偏瘫伴偏身感觉障碍患者基础上,如辅以低频电刺激患者偏瘫侧肢体周嗣神经,可进一步改善患者肢体感觉、运动功能及ADL能力.     

硝苯地平长效与短效制剂对高血压患者生活质量的作用比较

目的：探讨二氢吡啶类钙通道阻滞剂硝苯地平的长效制剂拜新同（nifedipine GITS,硝苯地平控释片）与短效制剂心痛定（nifedipine,硝苯地平）对轻中度高血压患者治疗作用与生活质量的影响。方法：两周停药“冲洗期”后,120例轻中度高血压病人（舒张压95-140mmHg）被随机分配到拜新同组（口服30mg,每日1次）或心痛定组（口服10mg,每日3次）,疗程共3个月,治疗前后分别记录血压和填写生活质量量表。评价治疗前后治疗3个朋后生活质量的改变。结果：降压疗效两组没有显著差别,血压下降拜新同组为15/13mmHg,心痛定组为16/12mmHg(P＞0.05);两组不良反应也无显著差别;拜新同组生活质量三个分量表得分均有明显改善,心痛定组躯体功能与心理健康得到改善,社会功能分量表质量下降,但无显著差别。结论：拜新同与心痛定降压治疗安全、有效,可改善患者的生活质量,两者比较拜新同优于心痛定,为一种比较理想的降压药物。     

Blood pressure control in patients with mild to moderate essential hypertension switched from nifedipine gastrointestinal therapeutic system (GITS) 30 mg to nifedipine GITS 20 mg

BACKGROUND: Nifedipine gastrointestinal therapeutic system (GITS) is a once-daily formulation of nifedipine that provides sustained plasma nifedipine concentrations throughout the 24-hour dosing interval. OBJECTIVE: This study was undertaken to determine if adult patients with mild to moderate essential hypertension whose blood pressure had been controlled for > or = 3 months with nifedipine GITS 30 mg could be successfully switched to a 20-mg daily dose with continued antihypertensive efficacy. METHODS: This was a randomized, double-blind, parallel-group study. Patients entered a 1-week run-in period during which they continued to receive their usual antihypertensive medication, including nifedipine GITS 30 mg. After baseline assessment, patients entered a 6-week treatment period during which they were randomly assigned to receive nifedipine GITS 30 or 20 mg. Men and women were eligible to participate if they were > or = 55 years of age, had received a diagnosis of mild to moderate essential hypertension (sitting diastolic blood pressure [DBP] 95-114 mm Hg), and had exhibited good blood pressure control (sitting DBP < or = 90 mm Hg) while taking nifedipine GITS 30 mg once daily for > or = 3 months. Systolic blood pressure (SBP), DBP, and heart rate were recorded at baseline and after 1, 3, and 6 weeks of treatment. Adverse events were reported by patients. The responder rate was defined as the percentage of patients whose sitting DBP was < 95 mm Hg at the final study assessment. Results were based on the intent-to-treat analyses, which included data for all patients who received > or = 1 dose and had 1 postbaseline blood pressure assessment. Statistical significance was set at P < 0.05. RESULTS: Seventy-five patients entered the 1-week run-in period; 71 patients (94.7%) were randomized to treatment. Twenty-four patients received nifedipine GITS 30 mg for 43.0 +/- 3.3 days, and 47 patients received nifedipine GITS 20 mg for 42.5 +/- 6.7 days. Both groups exhibited a sustained decrease in blood pressure throughout the study; minor variations were not statistically significant. End-point SBP and DBP for the 30- and 20-mg groups were 135.5 +/- 9.8/81.7 +/- 5.4 mm Hg and 138.6 +/- 11.8/82.9 +/- 7.6 mm Hg, respectively. Changes from baseline in end-point SBP and DBP did not differ significantly between groups. At the end of treatment, goal DBP (< 95 mm Hg) was achieved by 24 of 24 patients (100%) receiving the 30-mg dose and 45 of 47 patients (95.7%) receiving the 20-mg dose. Blood pressure control (sitting DBP < 90 mm Hg) was achieved by 21 of 24 (87.5%) patients in the 30-mg group and 35 of 47 (74.5%) patients in the 20-mg group. The most commonly reported adverse event was headache; 2 patients discontinued the study because of adverse events. Overall, 9 of 24 patients (37.5%) in the 30-mg group and 14 of 47 patients (29.8%) in the 20-mg group experienced > or = 1 treatment-related adverse event. CONCLUSIONS: Patients whose mild to moderate essential hypertension is controlled with nifedipine GITS 30 mg once daily may be able to switch to 20 mg once daily with continued antihypertensive efficacy. In addition to safety and economic advantages, such a switch may be a reasonable alternative in patients with lower body weight or as an adjunct to existing antihypertensive therapy.     

A comparison of the effects of two modified release preparations of nifedipine-nifedipine retard 10 mg twice daily and nifedipine GITS 20 mg once daily--in the treatment of mild to moderate hypertension

A multicentre, randomised, double-blind, cross-over comparison of nifedipine GITS 20 mg once daily and nifedipine retard 10 mg twice daily in 49 patients with mild to moderate hypertension was conducted. Both treatments resulted in clinically significant trough blood pressure reductions (nifedipine GITS -10.1/-8.9 mmHg, nifedipine retard -7.5/-8.2 mmHg). The study demonstrated that nifedipine GITS was 'at least equivalent' to nifedipine retard in the reduction of trough diastolic blood pressure (one-sided lower 95% confidence limit, -1.2 mmHg). The overall incidence of adverse events (nifedipine GITS 25.5%, nifedipine retard 34.0%), as well as the incidences of headache (nifedipine GITS 8.5%, nifedipine retard 12.8%) and peripheral oedema (nifedipine GITS 2.1%, nifedipine retard 8.5%), was higher with nifedipine retard compared to nifedipine GITS. Nifedipine GITS 20 mg once daily is 'at least equivalent' to nifedipine retard 10 mg twice daily in patients with mild to moderate hypertension, as well as being better tolerated.     

点穴配合常规康复治疗脑卒中偏瘫疗效观察

目的观察点穴配合常规康复治疗脑卒中偏瘫患者运动障碍的疗效。方法58例脑卒中偏瘫患者随机分为治疗组30与对照组28例；治疗组采用常规康复及点穴治疗；对照组仅接受常规康复治疗，分别于治疗前和治疗后12周采用Fugl-Meyer量表（FMA）评定患者的肢体运动功能，采用改良巴氏指数（MBI）评定日常生活活动能力（ADL）。结果治疗前两组患者的上下肢FMA积分无显著性差异（P〉0．05）；治疗后，治疗组患者的FMA积分较治疗前改善（P〈0．05），且明显优于对照组（P〈0．01），MBI评分高于对照组（P〈0．05）。结论点穴配合常规康复治疗可促进脑卒中患者运动功能的恢复，且效果优于常规康复治疗。     

运动再学习对急性脑卒中偏瘫患者运动功能及日常生活活动能力的影响

目的探讨早期实施运动再学习方法对脑卒中偏瘫患者的康复价值。方法102例脑卒中偏瘫患者随机分成治疗组(52例)和对照组(50例)进行临床对照性研究,两组均接受常规的临床药物治疗,治疗组加入运动再学习方法治疗,分别于治疗后1个月、3个月时比较两组患者上、下肢Brunnstrom运动功能评价和日常生活活动能力恢复情况。结果(1)两组患者治疗前上、下肢运动功能差异无统计学意义;治疗后1个月、3个月上、下肢运动功能差异有统计学意义(分别P<0.05,P<0.01);(2)两组患者治疗前日常生活活动能力差异无统计学意义;治疗1个月、3个月差异有统计学意义(分别P<0.05,P<0.01)。结论运动再学习治疗方法可以有效地改善急性脑卒中偏瘫患者的肢体运动功能,提高日常生活活动能力,提高患者生存质量。     

Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes

Hypertension is a major cardiovascular risk factor, and its increasing prevalence is of great clinical concern. Despite the availability of numerous effective therapies, hypertension remains under-diagnosed and under-treated. Hypertension often coexists with other risk factors, and current guidelines recommend a multifactorial approach to management, with the aim of not only controlling blood pressure but also reducing overall cardiovascular risk. Nifedipine gastrointestinal therapeutic system (GITS) is a long-acting formulation of a calcium channel blocker. Once-daily dosing with nifedipine GITS has been shown to achieve smooth and continuous blood pressure control, identical to conventional first-line diuretic therapy. Small-scale clinical trials have also shown that nifedipine GITS positively affects markers of atherosclerotic disease, which may signify an additional clinical benefit, but this is yet to be demonstrated. The recently completed ACTION (A Coronary Disease Trial Investigating Outcome with Nifedipine GITS) trial provides further evidence that nifedipine GITS can be used safely in high-risk patients to treat angina, lower blood pressure and significantly improve clinical outcomes.     

急性脑卒中患者早期康复的临床研究

目的　对比研究早期康复治疗对脑卒中患者发病早期的神经功能缺损程度、平衡功能、运动功能及日常生活活动能力 (ADL)的影响。方法　 64例急性脑卒中患者随机分为康复组及对照组 ,康复组采用综合疗法 (包括药物治疗、Bobath疗法、PNF疗法及神经肌肉电刺激等治疗 )。对照组采用药物治疗。 2 8d后分别评价两组患者的神经功能缺损程度、平衡功能、运动功能及ADL。结果　所有受试者治疗后神经功能缺损积分均明显减少 ,平衡功能、运动功能、ADL积分均明显增加 ,两组的变化均数相比 ,康复组优于对照组 (P<0 .0 5 )。结论　急性脑卒中患者早期综合康复与药物治疗相比 ,在降低其神经功能缺损积分 ,提高平衡功能、运动功能、ADL的积分上效果更好     

Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study

BACKGROUND: Angiotensin receptor blockers (ARBs) provide effective blood pressure control. Whereas none of the ARBs appear to affect glucose homeostasis, some ARBs have been associated with a decrease in cholesterolemia. OBJECTIVE: This study was conducted to evaluate blood pressure control glucose homeostasis, and the plasma lipid profile in patients with type 2 diabetes mellitus and mild hypertension during 12 months of treatment with the ARB telmisartan or nifedipine gastrointestinal therapeutic system (GITS). METHODS: In this double-blind trial, patients taking oral hypoglycemic agents were randomized to receive telmisartan 40 mg or nifedipine GITS 20 mg once daily for 12 months. At the time of enrollment, patients were given advice on diet (1400-1600 kcal/d) and exercise (stationary bicycle for > or =30 min, 4 d/wk). Assessments of systolic blood pressure (SBP), diastolic blood pressure, body mass index (BMI), fasting plasma glucose concentrations, glycosylated hemoglobin, fasting plasma insulin concentrations, the homeostasis model assessment of insulin resistance, and the lipid profile were performed at baseline and after 6 and 12 months of treatment. RESULTS: One hundred sixteen patients were divided into 2 age- and sex-matched treatment groups (58 men, 58 women; mean [SD] age, 52.5 [5] years). All patients were in good general health at baseline; had achieved adequate glycemic control with diet and oral hypoglycemic agents; were taking antihypercholesterolemic drugs; and had no evidence of macroangiopathy, microalbuminuria, or neuropathy. There were significant reductions from baseline in seated trough SBP after 12 months of treatment with both telmisartan and nifedipine GITS (from 139 [4] to 132 [4] mm Hg and from 140 [4] to 130 [4] mm Hg, respectively; both, P < 0.01). No change in BMI or glucose metabolism was observed with either treatment. After 12 months, there were significant improvements in concentrations of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) with telmisartan (-9% and -11.5%, respectively; both, P < 0.01) compared with nifedipine GITS (-2% and -1.5%). CONCLUSIONS: In this selected sample of patients with type 2 diabetes and mild hypertension, both telmisartan and nifedipine GITS produced significant reductions in blood pressure. Telmisartan was associated with a slight but statistically significant improvement in plasma TC and LDL-C concentrations compared with nifedipine GITS.     

偏瘫体操对脑卒中患者运动功能及日常生活活动能力的影响

目的观察偏瘫体操对脑卒中患者运动功能及日常生活活动能力的影响。方法将60例脑卒中偏瘫患者随机分为康复组和体操组,均接受常规PT、OT训练(采用神经发育促进技术),共8周。体操组在此基础上配合偏瘫体操训练。分别于治疗前、治疗8周后采用Fugl-Meyer评测法(FMA)评定两组患者的运动功能,采用改良Barthel指数(MBI)评定日常生活活动(ADL)能力,比较两组患者的评分变化。结果治疗前,两组患者的FMA和MBI评分差异无显著性意义(P>0.05);治疗后,体操组患者的评分明显优于康复组(P<0.01)。结论偏瘫体操结合常规康复训练可明显促进脑卒中偏瘫患者的运动功能及ADL能力。     

脑卒中患者肢体运动功能的综合康复治疗

目的：探讨综合康复治疗对脑卒中患者肢体运动功能恢复的影响。方法：采用促进技术为主,辅以高压氧,功能性电刺激,针灸等综合治疗方法对２０例脑卒中患者进行康复治疗。另２０例作为对照组,以Ｆｕｇｌ－Ｍｅｙｅｒ评分法,Ｂａｒｔｈｅｌ指数进行治疗前后的功能评定。结果：康复组在肢体运动功能,ＡＤＬ能力方面治疗后显著改善,与对照组相比,差异有显著性（Ｐ＜０．０１）。结论：以促进技术为主的康复治疗,有助于脑卒中患者尽快恢复功能。